Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.

Peterson LB, Bell CJM, Howlett SK, Pekalski ML, Brady K, Hinton H, Sauter D, Todd JA, Umana P, Ast O, Waldhauer I, Freimoser-Grundschober A, Moessner E, Klein C, Hosse RJ, Wicker LS.

J Autoimmun. 2018 Dec;95:1-14. doi: 10.1016/j.jaut.2018.10.017. Epub 2018 Nov 13.

2.

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P.

Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017.

3.

A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents.

Herter S, Morra L, Schlenker R, Sulcova J, Fahrni L, Waldhauer I, Lehmann S, Reisländer T, Agarkova I, Kelm JM, Klein C, Umana P, Bacac M.

Cancer Immunol Immunother. 2017 Jan;66(1):129-140. doi: 10.1007/s00262-016-1927-1. Epub 2016 Nov 17.

4.

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.

Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, Packman K, Feng N, Daouti S, Hosse RJ, Mössner E, Weber TG, Herting F, Scheuer W, Sade H, Shao C, Liu B, Wang P, Xu G, Vega-Harring S, Klein C, Bosslet K, Umaña P.

Mol Cancer Ther. 2016 May;15(5):946-57. doi: 10.1158/1535-7163.MCT-15-0647. Epub 2016 Apr 1.

5.

Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy.

Gonzalez-Nicolini V, Herter S, Lang S, Waldhauer I, Bacac M, Roemmele M, Bommer E, Freytag O, van Puijenbroek E, Umaña P, Gerdes CA.

Clin Cancer Res. 2016 May 15;22(10):2453-61. doi: 10.1158/1078-0432.CCR-14-2579. Epub 2015 Nov 18.

6.

Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis.

Laverman P, van der Geest T, Terry SY, Gerrits D, Walgreen B, Helsen MM, Nayak TK, Freimoser-Grundschober A, Waldhauer I, Hosse RJ, Moessner E, Umana P, Klein C, Oyen WJ, Koenders MI, Boerman OC.

J Nucl Med. 2015 May;56(5):778-83. doi: 10.2967/jnumed.114.152959. Epub 2015 Apr 9.

7.

Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.

Bell CJ, Sun Y, Nowak UM, Clark J, Howlett S, Pekalski ML, Yang X, Ast O, Waldhauer I, Freimoser-Grundschober A, Moessner E, Umana P, Klein C, Hosse RJ, Wicker LS, Peterson LB.

J Autoimmun. 2015 Jan;56:66-80. doi: 10.1016/j.jaut.2014.10.002. Epub 2014 Oct 30.

8.

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S, Duong MN, Reslan L, Gerdes CA, Friess T, Baer U, Burtscher H, Weidner M, Dumontet C, Umana P, Niederfellner G, Bacac M, Klein C.

Mol Cancer Ther. 2013 Oct;12(10):2031-42. doi: 10.1158/1535-7163.MCT-12-1182. Epub 2013 Jul 19.

9.

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.

Ferrara C, Grau S, Jäger C, Sondermann P, Brünker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, Umaña P, Benz J.

Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12669-74. doi: 10.1073/pnas.1108455108. Epub 2011 Jul 18.

10.

NK cells and cancer immunosurveillance.

Waldhauer I, Steinle A.

Oncogene. 2008 Oct 6;27(45):5932-43. doi: 10.1038/onc.2008.267. Review.

PMID:
18836474
11.

Tumor-associated MICA is shed by ADAM proteases.

Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG, Steinle A.

Cancer Res. 2008 Aug 1;68(15):6368-76. doi: 10.1158/0008-5472.CAN-07-6768.

12.

Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction.

Welte S, Kuttruff S, Waldhauer I, Steinle A.

Nat Immunol. 2006 Dec;7(12):1334-42. Epub 2006 Oct 22.

PMID:
17057721
13.

TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.

Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A, Weller M, Friese MA.

Brain. 2006 Sep;129(Pt 9):2416-25. Epub 2006 Aug 3.

PMID:
16891318
14.

Proteolytic release of soluble UL16-binding protein 2 from tumor cells.

Waldhauer I, Steinle A.

Cancer Res. 2006 Mar 1;66(5):2520-6.

Supplemental Content

Loading ...
Support Center